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In this issue ofCell StemCell, Ma et al. (2012) report a differentiation protocol for generating striatal projection
neurons from human embryonic stem cells with high efficiency. The cells survive transplantation, reconnect
striatal circuitry, and restore motor function in a mouse model of striatal neurodegeneration that mimics the
central pathohology of Huntington’s disease.Cell replacement therapy for neurological
disease, where lost neurons are replaced
with new ones, critically depends on
a readily available, renewable, and bank-
able source of cells to be used for trans-
plantation. The derivation of human
embryonic stem cells (hESCs) raised
hope for the creation of an unlimited
source of donor cells for neural transplan-
tation therapy (Thomson et al., 1998);
however, the hESC field has progressed
more slowly than originally anticipated,
facing challenges such as asynchronized
and uncontrolled hESC differentiation
into mixed populations of cells, their
propensity for tumor formation after graft-
ing, and their poor in vivo performance
(Go¨gel et al., 2011). In this issue of Cell
Stem Cell, Ma et al. (2012) report efficient
generation of striatal GABAergic projec-
tion neurons from hESCs that integrate
into host neural circuitry and correct
motor deficits in a mouse model of striatal
neurodegeneration.
The authors’ strategy was to modify
a monolayer differentiation protocol that
they had previously established to gen-
erate anterior neuroectodermal cells
(Pankratz et al., 2007). When combining
this protocol with timed and dosed
delivery of Sonic hedgehog (SHH), or
the small molecule purmorphamine, the
neural progenitors were efficiently pat-
terned into a ventral forebrain fate with
characteristics of cells in the lateral gangli-
onic eminence, the structure that gives
rise to striatal projection neurons during
embryonic development (see Figure 1).
Subsequent differentiation of these pro-
genitors yielded functional neurons that
produced GABA and expressed key
markers of striatal projection neurons at
a remarkably high frequency. Interestingly,addition of retinoic acid (RA) caudalized
the progenitors such that they maintained
their GABAergic phenotype but lost
their striatal characteristics. When grafted
to the lesioned mouse striatum, the
forebrain-patterned progenitors, but not
the caudalized progenitors, formed a
high proportion of cells with functional
and morphological properties of striatal
neurons. Only the forebrain-patterned
neurons, expressing aDARPP-32-positive
striatal phenotype, but not the caudalized
DARPP-32-negative GABAergic neurons,
could correct motor deficits in animal
models of neurodegeneration.
Although previous work had estab-
lished that striatal projection neurons
can be obtained from hESCs (Aubry
et al., 2008), the protocol described by
Zhang and colleagues reflects a signifi-
cant advancement as it is performed
under defined conditions, avoids the use
of feeder cells, and produces DARPP-
32-positive striatal neurons with much
higher efficiency (70%–80% of all cells in
the dish, compared with less than 20%
in the Aubry et al. study). Perhaps the
most significant advancement in the Ma
et al. study is the in vivo performance of
the cells. When grafted into the excito-
toxin model of striatal neurodegeneration,
which replicates the central pathology of
Huntington’s disease, the hESC-derived
striatal progenitors showed good survival
over a relatively long time frame. More-
over, the grafted cells exhibited an
impressively high degree of neuronal
differentiation with a high proportion of
GABAergic neurons expressing the char-
acteristic striatal marker DARPP-32 (over
50% of all cells in the grafts). The grafted
cells were shown to receive inputs from
the host brain and project to correct targetCell Stem Cestructures in the host, accompanied by
reversal of the motor deficits seen in the
excitotoxin-lesioned mice. Importantly,
the animals showed no signs of over-
growth or tumor formation, otherwise
associated with grafting of pluripotent
cells and immature forebrain-patterned
cells in particular (Aubry et al., 2008; Roy
et al., 2006).
The current study expands on a series
of recent advancements in the develop-
ment of protocols for directed neural
differentiation and generation of specific
subsets of CNS neurons from hESCs.
New protocols for neural induction have
resulted in faster, more synchronized,
and efficient generation of neural progen-
itors and neurons from hESCs (Chambers
et al., 2009; Pankratz et al., 2007). The
current study, as well as another recent
report (Kriks et al., 2011), shows that
when these neural differentiation proto-
cols are combined with more refined
strategies for regionalization of the
induced cellular phenotypes based on
developmental principles, it is possible
to generate functional subtype-specific
neurons in large numbers that survive
and form neuron-rich and tumor-free
grafts after transplantation. Importantly,
the striatal neurons generated by Ma
et al., and the dopamine neurons gener-
ated by Studer and colleagues, were
shown to be functionally efficacious in
animal models that replicate central neu-
rodegenerative features of Huntington’s
and Parkinson’s disease, respectively.
It should also be noted that recent
developments in cellular reprogramming
have opened up new avenues for obtain-
ing human neurons for cell therapy and
other applications. The ability to repro-
gram the identity of easily accessiblell 10, April 6, 2012 ª2012 Elsevier Inc. 349
Figure 1. Application of the Developmental Inductive Signals SHH and RA Enables
Differentiation of Defined Subsets of Neurons from hESCs
Schematic diagram illustrating the expression of Sonic hedgehog (SHH) along the ventral midline (blue)
and the gradient of its concentration in the ventral forebrain which was used to give the cells a ventral,
striatal identity. The rostro-caudal gradient of the caudalizing factor retinoic acid (RA), used in this study,
is shown in red. Primitive neuroepithelial cells were patterned with SHH to generate lateral ganglionic
eminence (LGE) progenitors that subsequently differentiated into striatal projection neurons in vitro and
after transplantation in vivo. When the neuroepithelial cells were exposed to SHH as well as RA,
GABAergic spinal cord neurons were formed. When transplanted to the quinolinic-acid-lesioned striatum,
the striatal, but not the spinal cord, GABAergic neurons promoted recovery in behavioral tests. MGE,
medial ganglionic eminence.
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Previewssomatic cells into induced pluripotent
cells (iPSCs) that can subsequently be
differentiated into neurons, or directly
into induced neurons (iN cells), has
entered two new players into the field,
capable of providing patient- and
disease-specific neurons on demand
(Chambers and Studer, 2011). In this
new arena, ESCs are up for a tough
competition. While iPSCs suffer from
the same safety concerns as ESCs, the
ethical issues are less problematic and
the ability to make donor-matched
neurons offers a distinct advantage.
Human iN cells obtained by direct con-350 Cell Stem Cell 10, April 6, 2012 ª2012 Elversion of somatic cells are the youngest
players in the field and have yet to prove
survival and efficacy in animal models of
neurodegenerative disease. Neverthe-
less, the fact that these cells do not pass
through a pluripotent state reduces the
risk of uncontrolled proliferation and
speeds up the conversion process.
The recent advancements in hESC
differentiation and specification suggest
that when the neuralization of hESCs is
efficient and synchronized and recapitu-
lates developmental signals for regionali-
zation and subtype-specific differentia-
tion, the resulting neurons are authentic,sevier Inc.survive well, and do not form tumors in
the host brain after transplantation, taking
this strategy one step closer to clinical
translation. However, more roadblocks
have to be passed before hESCs are
ready for clinical use. The use of ESCs
as starting material is fraught with ethical
issues, in addition to safety concerns
associated with their pluripotent nature.
Cell potency assays directly comparing
the restorative potential of hESC-derived
neurons to that of fetal neurons known
to function in a clinical setting also need
to be performed before progressing to
the clinic. Furthermore, the absence of
unwanted proliferation after grafting has
to be much more rigorusly tested in
different models (including primates)
and over longer time frames before
clinical use can be considered (Lindvall
et al., 2012). Despite these hurdles, the
current advancements in the generation
of fully functional striatal projection
neurons from hESCs are an important
step forward.REFERENCES
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